LVCLY
Living Cell Technologies Ltd.
PAL: BNY Mellon
OTCQX International
Contact Info
- Level 3, Suite 302
- 70 Pitt Street
- GPO Box 4231
- Sydney, NSW 2001
- Australia
- Website: http://www.lctglobal.com/
- Phone: +61 1300 134 875
Update Company Info
Business Description
Living Cell Technologies Ltd (ASX:LCT) develops live cell-based therapy products to treat life-threatening human diseases. The company's most advanced product treats type 1 diabetes by implanting microencapsulated porcine islet cells. This achieves near-normal blood-glucose levels with healthy living cells injected into patients to replace damaged tissue, without requiring immunosuppresive drugs to prevent rejection.
Financial Reporting/Disclosure
| Reporting Status | International Reporting: ASX - Australian Securities Exchange |
| Audited Financials | Audited |
| Latest Report | Apr 29, 2012 Quarterly Report |
| Regulatory Agency | Not Available |
| CIK | 0001398773 |
| Fiscal Year End | 6/30 |
| OTC Market Tier | OTCQX International |
Profile Data
| SIC - Industry Classification | 2836 - Biological products, except diagnostic |
| Incorporated In: | Australia |
| Year of Inc. | 2003 |
| Employees | 49 a/o Nov 01, 2006 |
Company Officers
| Andrea Grant | CEO |
| Nicholas Geddes | Secretary |
| John Cowan | Finance Manager |
| Bob Elliott | Medical Director |
Company Directors
| Roy Austin | Chairman |
| Laurie Hunter | |
| Bernard Tuch | |
| Robert Willcock |
Service Providers
DAD/PAL Auditor/Accountant Legal Counsel
Not Available
Investor Relations Firm
LVCLY Security Details Other Company Securities
Share Structure
| Market Value1 | $15,599,520 | a/o May 23, 2012 |
| Shares Outstanding | 339,120,000 | a/o Dec 31, 2011 |
| Float | 257,770,000 | a/o Dec 31, 2011 |
| Authorized Shares | Not Available | |
| Par Value | No Par Value |
Shareholders
| Shareholders of Record | Not Available |
Non US Stock Exchange Listing
| LCT - ASX - Australian Securities Exchange - Qualified |
Short Selling Data
| Short Interest | 3,670 (-54.75%) Apr 30, 2012 |
| Significant Failures to Deliver | No |
Transfer Agent(s)
| BNY Mellon |
1Market Value calculated only for respective security
